Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

466.24
+5.701.24%
Volume:185.31K
Turnover:85.59M
Market Cap:61.60B
PE:1.41K
High:466.24
Open:458.15
Low:456.27
Close:460.54
52wk High:495.55
52wk Low:205.87
Shares:132.11M
Float Shares:126.15M
Volume Ratio:0.56
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3299
EPS(LYR):-2.1790
ROE:32.73%
ROA:3.65%
PB:263.35
PE(LYR):-213.97

Loading ...

Alnylam Pharma (ALNY) Gets a Buy from Chardan Capital

TIPRANKS
·
Oct 31

Alnylam Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
Oct 31

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?

Benzinga
·
Oct 31

Alnylam price target raised to $495 from $475 at Morgan Stanley

TIPRANKS
·
Oct 31

Alnylam price target lowered to $549 from $550 at Jefferies

TIPRANKS
·
Oct 31

Stock Track | Alnylam Pharmaceuticals Plummets 8.38% Despite Blowout Q3 Earnings and Raised Guidance

Stock Track
·
Oct 30

Stock Track | Alnylam Pharmaceuticals Plunges 8.38% Despite Strong Q3 Results and Raised Guidance

Stock Track
·
Oct 30

Alnylam Pharmaceuticals Shares Fall 2.2% After Q3 Results

THOMSON REUTERS
·
Oct 30

Alnylam reports Q3 EPS $1.84, consensus $1.75

TIPRANKS
·
Oct 30

Alnylam Pharmaceuticals Shares Fall 7.6% Premarket After Q3 Results

THOMSON REUTERS
·
Oct 30

Stock Track | Alnylam Pharmaceuticals Plunges 5.52% Pre-Market Despite Strong Q3 Results, Raised Guidance

Stock Track
·
Oct 30

Stock Track | Alnylam Pharmaceuticals Plunges 5.52% Pre-Market Despite Strong Q3 Results and Raised Guidance

Stock Track
·
Oct 30

Alnylam beats Q3 revenue estimates, up FY forecast

Reuters
·
Oct 30

Alnylam Pharmaceuticals reports third-quarter 2025 revenue of $1.25 billion and net income of $251 million

Reuters
·
Oct 30

BRIEF-Alnylam Pharmaceuticals Q3 Adjusted EPS USD 3.01 Vs. IBES Estimate USD 0.42

Reuters
·
Oct 30

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

THOMSON REUTERS
·
Oct 30

Alnylam Pharmaceuticals - Outlook 2025 Total Net Product Revenues $2,950 Million to $3,050 Million

THOMSON REUTERS
·
Oct 30

Alnylam Pharmaceuticals Q3 Adjusted EPS USD 3.01 VS. Ibes Estimate USD 0.42

THOMSON REUTERS
·
Oct 30

Alnylam Pharmaceuticals Q3 Net Product Revenue USD 1,249.026 Million VS. Ibes Estimate USD 946 Million

THOMSON REUTERS
·
Oct 30

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 30